ES2112921T3 - Peptidos y anticuerpos para el tratamiento de la artritis reumatoide. - Google Patents

Peptidos y anticuerpos para el tratamiento de la artritis reumatoide.

Info

Publication number
ES2112921T3
ES2112921T3 ES92923909T ES92923909T ES2112921T3 ES 2112921 T3 ES2112921 T3 ES 2112921T3 ES 92923909 T ES92923909 T ES 92923909T ES 92923909 T ES92923909 T ES 92923909T ES 2112921 T3 ES2112921 T3 ES 2112921T3
Authority
ES
Spain
Prior art keywords
peptides
antibodies
treatment
rheumatoid arthritis
necessarily adjacent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92923909T
Other languages
English (en)
Inventor
Julian Kirby
Ian Victor Lewin
Sarita Maman
Denis Raymond Stanworth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Holding Ltd
Original Assignee
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptide Therapeutics Ltd filed Critical Peptide Therapeutics Ltd
Application granted granted Critical
Publication of ES2112921T3 publication Critical patent/ES2112921T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

UN PEPTIDO SINTETICO DE NO MAS DE 20 RESIDUOS DE AMINOACIDOS O ANALOGOS DE ELLOS, COMPRENDE UN RESIDUO DE CISTEINA TIOL-ACTIVA Y AL MENOS DOS RESIDUOS DE AMINOACIDOS CARGADOS POSITIVAMENTE SITUADOS SOBRE (PERO NO NECESARIAMENTE ADYACENTES A ) EL LATERAL TERMINAL-N, SOBRE (PERO NO NECESARIAMENTE ADYACENTES A ) EL LATERAL TERMINAL-C O SOBRE (PERO NO NECESARIAMENTE ADYACENTES A ) AMBOS TERMINALES-C,-N DE LA CISTEINA TIOL-ACTIVA DE USO TERAPEUTICO.
ES92923909T 1991-11-25 1992-11-25 Peptidos y anticuerpos para el tratamiento de la artritis reumatoide. Expired - Lifetime ES2112921T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919125024A GB9125024D0 (en) 1991-11-25 1991-11-25 Rheumatoid arthritus treatment

Publications (1)

Publication Number Publication Date
ES2112921T3 true ES2112921T3 (es) 1998-04-16

Family

ID=10705197

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92923909T Expired - Lifetime ES2112921T3 (es) 1991-11-25 1992-11-25 Peptidos y anticuerpos para el tratamiento de la artritis reumatoide.

Country Status (10)

Country Link
EP (1) EP0614464B1 (es)
JP (1) JPH07507045A (es)
AT (1) ATE163939T1 (es)
AU (2) AU2951392A (es)
CA (1) CA2123694A1 (es)
DE (1) DE69224750D1 (es)
ES (1) ES2112921T3 (es)
FI (1) FI942392A0 (es)
GB (2) GB9125024D0 (es)
WO (1) WO1993011153A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9416864D0 (en) * 1994-08-19 1994-10-12 Peptide Therapeutrics Limited Treatment of IgA nephropathy
GB9416865D0 (en) * 1994-08-19 1994-10-12 Peptide Therapeutrics Limited Treatment of inflammatory diseases of the gastro-intestinal tract
HUP9901109A3 (en) 1996-03-01 1999-11-29 Novartis Ag Peptide immunogens for vaccination against and treatment of allergy
AU2001270098A1 (en) * 2000-06-22 2002-01-02 San Diego State University Foundation Recombination modulators and methods for their production and use
EP2671891A3 (en) 2008-06-27 2014-03-05 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US11918624B2 (en) 2020-06-10 2024-03-05 Kelsius Laboratories LLC Therapeutic composition for use in the treatment of COVID-19 and other cytokine storm associated disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2938420A1 (de) * 1979-09-22 1981-04-09 Hoechst Ag, 6000 Frankfurt Neue peptide und verfahren zu ihrer herstellung
AU572173B2 (en) * 1983-08-29 1988-05-05 Institut De Recherches Cliniques De Montreal Natriuretic factors
US4701416A (en) * 1983-12-09 1987-10-20 Cetus Corporation Feline leukemia virus vaccine plasmids for fusion protein of the gp70 envelope protein of FELV
US4692511A (en) * 1984-07-03 1987-09-08 Immunetech Pharmaceuticals Peptide antagonists for the C5a anaphylatoxin
EP0235391B1 (en) * 1985-12-26 1992-06-10 The University of Saskatchewan Peptides corresponding to antigenic and immunogenic determinants of major neutralizing proteins of rotaviruses
GB8616174D0 (en) * 1986-07-02 1986-08-06 Antibody Technology Ltd Monoclonal antibodies
DK268889A (da) * 1988-06-07 1989-12-08 Smithkline Beckman Corp Cykliske d-cys6-peptidforbindelser, fremgangsmaader til fremstilling heraf samt farmaceutiske midler indeholdende disse
ATE134195T1 (de) * 1988-06-10 1996-02-15 United Biomedical Inc Peptidfragmente von hiv
FR2646425B1 (fr) * 1989-04-26 1991-08-30 Neosystem Sa Peptides synthetiques du conjugue de l'ubiquitine et de l'histone h2a
EP0860504A1 (en) * 1989-05-08 1998-08-26 Idexx Laboratories, Inc. Polypeptides of feline T-cell lymphotropic lentivirus
ES2077857T3 (es) * 1990-05-25 1995-12-01 Peptide Therapeutics Ltd Prueba de inmunodiagnostico para artritis reumatoide.
CA2060699A1 (en) * 1991-02-11 1992-08-12 Isia Bursuker Gm-csf inhibiting oligopeptides

Also Published As

Publication number Publication date
EP0614464B1 (en) 1998-03-11
FI942392A (fi) 1994-05-24
GB2261665B (en) 1995-11-08
GB9125024D0 (en) 1992-01-22
ATE163939T1 (de) 1998-03-15
DE69224750D1 (de) 1998-04-16
GB2261665A (en) 1993-05-26
CA2123694A1 (en) 1993-06-10
EP0614464A1 (en) 1994-09-14
JPH07507045A (ja) 1995-08-03
GB9224684D0 (en) 1993-01-13
WO1993011153A1 (en) 1993-06-10
AU7196596A (en) 1997-02-06
FI942392A0 (fi) 1994-05-24
AU2951392A (en) 1993-06-28

Similar Documents

Publication Publication Date Title
ATE442159T1 (de) Parathyroidhormon analoge
DE69839812D1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
CO4890856A1 (es) CICATRIZACION DE FRACTURAS USANDO ANALOGOS DE PTHrP
DE69129865T2 (de) Osteogene peptide
ES2174770T1 (es) Peptidos diseñados para el diagnostico y el tratamiento de artritis reumatoide.
DK156592D0 (da) Human-h1-praeprorelaxin, -prorelaxin og -relaxin samt polypeptid med relaxinaktivitet og fremgangsmaade til sammenfoejning af a- og b-kaederne i human-h1-relaxin
ES548617A0 (es) Procedimiento para disociar peptidos y proteinas en el enla-ce metionilo
BR9306272A (pt) Peptídeo e composiçao farmacêutica
ES2112921T3 (es) Peptidos y anticuerpos para el tratamiento de la artritis reumatoide.
ES2094160T3 (es) Peptidos terapeuticos, en particular analogos del peptido substancia p.
NO941415D0 (no) Polypeptider og deres anvendelse for å nöytralisere antistoffer
ATE31314T1 (de) Cyclische peptide mit somatostatin-wirkung.
DE3852588D1 (de) Biologisch aktive Moleküle.
PE20000931A1 (es) Nuevos peptidos para uso en la inmunoterapia de enfermedades autoinmunes
DK1612555T3 (da) Kryptiske peptider til anvendelse til at inducere immunologisk tolerance
TR199901831T2 (xx) Kollagen-II'ye �zg� bir T-h�cresi epitopundan olu�an peptitler.
ES2114004T3 (es) Procedimiento de preparacion de peptidos con un residuo prolina amidado en la posicion c-terminal.
SE9100284D0 (sv) Novel peptide
ES2112311T3 (es) Vacuna acelular.
DK0423326T3 (da) Hidtil ukendt fysiologisk aktivt peptid og calcium-metabolisme-regulerende middel, der omfatter peptidet som effektiv besta
ECSP961741A (es) Insulina de caneda sencilla con alta bioactividad (
DK119391A (da) Humaninsulinanaloger

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 614464

Country of ref document: ES